Jérémy Lecot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jérémy Lecot has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Chloé Bruneau
Grand Ouest" Poison Control Center, University Hospital of Angers, 4 Rue Larrey, F-49933, Angers 9, France
4 shared publications- Gaël Le Roux
‘Grand Ouest’ Poison Control Center University Hospital of Angers Angers France
3 shared publications Marie Deguigne
Centre antipoison Grand Ouest, CHU Angers
3 shared publicationsAlexis Descatha
Poison Control Center Angers University Hospital (CHU Angers) Angers France
2 shared publicationsAnne Garat
Centre Antipoison de Lille, CHU de Lille
2 shared publicationsAnne Landreau
University of Angers, Faculty of Health, F-49000, Angers, France; University of Angers, University of Brest, IRF, SFR ICAT, F-49000, Angers, France
2 shared publications
Latest Publications
- 15 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-2
Voluntary levamisole intoxication: a rare case of reversible neurological toxicity without cocaine co-ingestion
Dear Editor,A 24-year-old man with no significant medical or psychiatric history intentionally injected 1,500 mg of Nemizole® (levamisole), a veterinary antiparasitic agent purchased from a pet sto...
- 15 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-2
Voluntary levamisole intoxication: a rare case of reversible neurological toxicity without cocaine co-ingestion
Dear Editor,A 24-year-old man with no significant medical or psychiatric history intentionally injected 1,500 mg of Nemizole® (levamisole), a veterinary antiparasitic agent purchased from a pet sto...
- 20 January 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-8
Tropatepine poisoning and management: a series of 458 cases
Tropatepine is an antiparkinsonian drug that can be associated with antimuscarinic delirium in overdose. Two acetylcholinesterase inhibitors, neostigmine and physostigmine, are available for the management of tropatepine poisoning. The aim of this study is to describe a series of tropatepine poisonings and to compare the management of patients. This epidemiological, retrospective, multicentre study reviewed tropatepine intoxications reported to French poison centres from 1 January 2000 to 13 July 2023. The relationship between reduction in central antimuscarinic signs and associated risk factors was assessed by univariate and multivariate logistic regression. A total of 458 cases of tropatepine poisoning were included. Peripheral and central antimuscarinic signs were observed in 214 (46.7%) and 102 patients (22.3%), respectively. For patients who ingested tropatepine alone (n = 94), 29 (30.8%) showed agitation or delirium. A reported median ingested dose of 270 mg of tropatepine was associated with the onset of central and peripheral antimuscarinic signs, compared with 100 mg for peripheral signs alone (P = 0.0012). The median (IQR) duration of central antimuscarinic signs was 24 h (12-48 h). Agitation was treated by neostigmine and physostigmine in 25 and 13 patients, respectively. In 16 (76%) patients treated with neostigmine, there was no improvement in central signs, whereas 13 (100%) patients responded favorably to physostigmine. After adjustment for ingested dose, the complete resolution of central antimuscarinic signs was significantly higher in patients treated with physostigmine than with neostigmine (odds ratio 6.61; 95% CI: 1.00-44.94]; P = 0.0499). Due to its long elimination half-life, tropatepine poisoning is frequently associated with a severe and prolonged antimuscarinic syndrome. Caring for these agitated patients requires substantial input from nursing staff. Physostigmine is still little used but appears to be effective in controlling the central antimuscarinic syndrome induced by tropatepine.
- 20 January 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-8
Tropatepine poisoning and management: a series of 458 cases
Tropatepine is an antiparkinsonian drug that can be associated with antimuscarinic delirium in overdose. Two acetylcholinesterase inhibitors, neostigmine and physostigmine, are available for the management of tropatepine poisoning. The aim of this study is to describe a series of tropatepine poisonings and to compare the management of patients. This epidemiological, retrospective, multicentre study reviewed tropatepine intoxications reported to French poison centres from 1 January 2000 to 13 July 2023. The relationship between reduction in central antimuscarinic signs and associated risk factors was assessed by univariate and multivariate logistic regression. A total of 458 cases of tropatepine poisoning were included. Peripheral and central antimuscarinic signs were observed in 214 (46.7%) and 102 patients (22.3%), respectively. For patients who ingested tropatepine alone (n = 94), 29 (30.8%) showed agitation or delirium. A reported median ingested dose of 270 mg of tropatepine was associated with the onset of central and peripheral antimuscarinic signs, compared with 100 mg for peripheral signs alone (P = 0.0012). The median (IQR) duration of central antimuscarinic signs was 24 h (12-48 h). Agitation was treated by neostigmine and physostigmine in 25 and 13 patients, respectively. In 16 (76%) patients treated with neostigmine, there was no improvement in central signs, whereas 13 (100%) patients responded favorably to physostigmine. After adjustment for ingested dose, the complete resolution of central antimuscarinic signs was significantly higher in patients treated with physostigmine than with neostigmine (odds ratio 6.61; 95% CI: 1.00-44.94]; P = 0.0499). Due to its long elimination half-life, tropatepine poisoning is frequently associated with a severe and prolonged antimuscarinic syndrome. Caring for these agitated patients requires substantial input from nursing staff. Physostigmine is still little used but appears to be effective in controlling the central antimuscarinic syndrome induced by tropatepine.
- Open Access
Emerging mycotoxic syndromes in France: Epidemiological trends and public health implications (2015–2022)
- 21 January 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (3) , 221-222
Delayed cerebrospinal fluid removal is ineffective in treating intrathecal baclofen overdose
- 21 January 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (3) , 221-222
Delayed cerebrospinal fluid removal is ineffective in treating intrathecal baclofen overdose
- 2 November 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (11) , 1010-1011
The potential of keratinized matrices for the retrospective exploration of repeated ayahuasca use by patients
- 2 November 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (11) , 1010-1011
The potential of keratinized matrices for the retrospective exploration of repeated ayahuasca use by patients
- 20 March 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 132 (6) , 528-537
Cyclopeptide mushroom poisoning: A retrospective series of 204 patients
Cyclopeptide mushroom poisoning is responsible for 90%–95% of deaths from macrofungi ingestion. The main objectives of this study are to describe cases of cyclopeptide mushroom poisoning and to determine risk factors that may influence the severity/mortality of poisoned patients. We included all cases of amatoxin toxicity reported to two French Poison Centers from 2013 through 2019. We compared the severity with the Poison Severity Score (PSS) and the outcomes of patients using simple logistic regression and multinomial logistic regression. We included 204 cases of amatoxin toxicity. More than three‐quarters developed an increase in AST and/or ALT (78.1%), and over half developed a decrease in prothrombin ratio (p < 0.05). Patients who died or developed post‐poisoning sequelae had more frequent cardiovascular comorbidities compared with recovered patients (60.0% versus 29.5%; p < 0.01).
- 20 March 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 132 (6) , 528-537
Cyclopeptide mushroom poisoning: A retrospective series of 204 patients
Cyclopeptide mushroom poisoning is responsible for 90%–95% of deaths from macrofungi ingestion. The main objectives of this study are to describe cases of cyclopeptide mushroom poisoning and to determine risk factors that may influence the severity/mortality of poisoned patients. We included all cases of amatoxin toxicity reported to two French Poison Centers from 2013 through 2019. We compared the severity with the Poison Severity Score (PSS) and the outcomes of patients using simple logistic regression and multinomial logistic regression. We included 204 cases of amatoxin toxicity. More than three‐quarters developed an increase in AST and/or ALT (78.1%), and over half developed a decrease in prothrombin ratio (p < 0.05). Patients who died or developed post‐poisoning sequelae had more frequent cardiovascular comorbidities compared with recovered patients (60.0% versus 29.5%; p < 0.01).
- 1 February 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (2) , 142
Comment on: amanitin intoxication
Dear Editor,We have read with interest the paper “Amanitin intoxication: effects of therapies on clinical outcomes – a review of 40 years of reported cases” [1].There are no worldwide accepted guid...
- 1 February 2023
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 61 (2) , 142
Comment on: amanitin intoxication
Dear Editor,We have read with interest the paper “Amanitin intoxication: effects of therapies on clinical outcomes – a review of 40 years of reported cases” [1].There are no worldwide accepted guid...